CSS LLC’s BioMarin Pharmaceuticals BMRN Stock Holding History

CSS LLC’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.29M	Buy	22,580 +6,600	+41%	+$362K	0.05%	268
2026 Q1	$903K	Sell	15,980 -5,200	-25%	-$303K	0.04%	369
2025 Q4	$1.26M	Sell	21,180 -2,780	-12%	-$151K	0.06%	259
2025 Q3	$1.3M	Buy	23,960 +12,650	+112%	+$723K	0.06%	256
2025 Q2	$622K	Buy	+11,310	New	+$666K	0.03%	483
2024 Q2	–	Sell	-3,600	Closed	-$314K	–	903
2024 Q1	$314K	Hold	3,600	–	–	0.02%	561
2023 Q4	$347K	Hold	3,600	–	–	0.02%	522
2023 Q3	$319K	Buy	+3,600	New	+$320K	0.02%	498
2017 Q2	–	Sell	-3,863	Closed	-$351K	–	641
2017 Q1	$339K	Hold	3,863	–	–	0.02%	400
2016 Q4	$320K	Buy	3,863 +650	+20%	+$55.9K	0.02%	426
2016 Q3	$297K	Buy	+3,213	New	+$303K	0.01%	482

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

CSS LLC's BMRN Position: Q2 2026 in Review

CSS LLC increased its BioMarin Pharmaceuticals (BMRN) stake by 41% in Q2 2026, buying an estimated $362K and bringing the position to 22,580 shares worth $1.29M. The position accounts for 0.05% of the portfolio, ranked #268.

CSS LLC first reported a position in BMRN in Q3 2016 and has held it in 11 quarters since. The position peaked at $1.3M in Q3 2025. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

CSS LLC held 22,580 shares of BioMarin Pharmaceuticals worth $1.29M as of Q2 2026.
CSS LLC bought 6,600 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $362K.
BioMarin Pharmaceuticals made up 0.05% of CSS LLC's portfolio in Q2 2026, its #268 holding.
CSS LLC first reported a position in BioMarin Pharmaceuticals in Q3 2016 and has held it in 11 quarters since.
CSS LLC's BioMarin Pharmaceuticals position peaked at $1.3M in Q3 2025.
564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on CSS LLC's 13F filing for Q2 2026, filed 14 Aug 2026.